Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 168 participants.

Also called NCT01375751

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 168 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01375751
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01375751. Randomized; quadruple masking; primary purpose treatment. Start 2011-08-02 (actual); primary completion 2012-05-16 (actual). Results posted on 2015-09-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Acronym
RUTHERFORD
Condition
Hypercholesterolemia, Familial
Intervention (Biological)
Evolocumab
Intervention (Biological)
Placebo
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01375751
Content hash
693cfb3ea15746aca437644d3a18e3c13f4a5e2b73e83e4a8497cb98fc043b43